Home / Technology & Devices (page 2)

Technology & Devices

FDA Approves Myriad’s BRACAnalysis CDx as Companion Diagnostic for Lynparza in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer

SALT LAKE CITY, Dec. 19, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with advanced ovarian cancer who have a germline BRCAmutation …

Read More »

X-Chem Enters Strategic Collaboration with Bristol-Myers Squibb

WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) library drug discovery engine to the generation of novel small molecule therapeutics, today announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb. The collaboration will enable the discovery of novel lead …

Read More »

Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology

THOUSAND OAKS, Calif. and ZURICH-SCHLIEREN, Switzerland, Dec. 18, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Molecular Partners AG(SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin®therapeutics, today announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical …

Read More »

Guardant Health Partners with AstraZeneca to Develop Blood-Based Companion Diagnostic Tests for Tagrisso and Imfinzi

REDWOOD CITY, Calif., Dec. 13, 2018 (GLOBE NEWSWIRE) — Guardant Health (Nasdaq: GH) announced a multi-year agreement with AstraZeneca (NYSE: AZN) to develop blood-based companion diagnostic (CDx) tests supporting the commercialization of AstraZeneca’s oncology portfolio based on Guardant’s industry-leading comprehensive liquid biopsy platform. Under the terms of the agreement, Guardant …

Read More »

Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET Immunotherapy Drug Candidates

WALTHAM, Mass., Dec. 13, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced it has licensed two TriNKET™ immunotherapy drug candidates to Celgene Corporation and its affiliates (“Celgene”) for $12m each plus prospective milestones and royalties.  The licenses represent the first two of four hematological cancer targets …

Read More »

Roche to Develop Companion Diagnostic Test to Identify Patients Eligible for Anti-PD-1 Therapy Based on Biomarker Expression

TUCSON, Ariz., Dec. 11, 2018 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it entered into a collaboration with Merck (known as MSD outside the United States and Canada) to develop a companion diagnostic test to identify patients eligible for anti-PD-1 therapy based on the status of …

Read More »

10x Genomics Acquires Spatial Transcriptomics

PLEASANTON, Calif., Dec. 10, 2018 /PRNewswire/ — 10x Genomics today announced the acquisition of Stockholm-based Spatial Transcriptomics, a pioneer in the emerging field of spatial genomics. The new field enables researchers to not only see what is in a cell but how cells are organized in relation to one another, …

Read More »

Myriad Study Demonstrates EndoPredict Can Guide Chemotherapy Decision for Women with Early-Stage Breast Cancer

SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that academic researchers from the Technical University of Munich (TUM) presented the first prospective outcomes data on EndoPredict® at the San Antonio Breast Cancer Symposium in San Antonio, Texas.  …

Read More »

TATAA Biocenter Expands Its Next-Generation Sequencing Offerings with HTG Molecular Diagnostics’ Unique HTG EdgeSeq System

GÖTEBORG, Sweden and TUSCON, Ariz., Dec. 05, 2018 (GLOBE NEWSWIRE) — TATAA Biocenter, Europe’s leading provider of genomic services, and HTG Molecular Diagnostics, Inc (HTG) (Nasdaq: HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the expansion of TATAA Biocenter’s next-generation sequencing (NGS) offerings with …

Read More »

Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla Oncotype DX Genomic Prostate Score Test

REDWOOD CITY, Calif., United States, and MECHELEN, Belgium, 3 December 2018 – Genomic Health, Inc. the world’s leading provider of genomic-based diagnostic tests (NASDAQ: GHDX) and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announce they have expanded their exclusive collaboration into the field of urology with the development of an in …

Read More »